1
|
Kim DI, Song MK, Yuk JE, Seo HJ, Lee K. Establishment of an artificial particulate matter-induced lung disease model through analyzing pathological changes and transcriptomic profiles in mice. Sci Rep 2023; 13:5955. [PMID: 37045933 PMCID: PMC10097713 DOI: 10.1038/s41598-023-29919-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Accepted: 02/13/2023] [Indexed: 04/14/2023] Open
Abstract
Particulate matter (PM), an environmental risk factor, is linked with health risks such as respiratory diseases. This study aimed to establish an animal model of PM-induced lung injury with artificial PM (APM) and identify the potential of APM for toxicological research. APM was generated from graphite at 600 °C and combined with ethylene. We analyzed diesel exhaust particulate (DEP) and APM compositions and compared toxicity and transcriptomic profiling in lungs according to the exposure. For the animal study, C57BL/6 male mice were intratracheally administered vehicle, DEP, or APM. DEP or APM increased relative lung weight, inflammatory cell numbers, and inflammatory protein levels compared with the vehicle control. Histological assessments showed an increase in particle-pigment alveolar macrophages and slight inflammation in the lungs of DEP and APM mice. In the only APM group, granulomatous inflammation, pulmonary fibrosis, and mucous hyperplasia were observed in the lungs of some individuals. This is the first study to compare pulmonary toxicity between DEP and APM in an animal model. Our results suggest that the APM-treated animal model may contribute to understanding the harmful effects of PM in toxicological studies showing that APM can induce various lung diseases according to different doses of APM.
Collapse
Affiliation(s)
- Dong Im Kim
- Jeonbuk Department of Inhalation Research, Inhalation Toxicology Center for Airborne Risk Factor, Korea Institute of Toxicology, 30 Baekhak1-Gil, Jeongeup, Jeollabuk-Do, 56212, Republic of Korea
| | - Mi-Kyung Song
- Jeonbuk Department of Inhalation Research, Inhalation Toxicology Center for Airborne Risk Factor, Korea Institute of Toxicology, 30 Baekhak1-Gil, Jeongeup, Jeollabuk-Do, 56212, Republic of Korea
- Department of Human and Environmental Toxicology, University of Science & Technology, Daejeon, 34113, Republic of Korea
| | - Ji Eun Yuk
- Jeonbuk Department of Inhalation Research, Inhalation Toxicology Center for Airborne Risk Factor, Korea Institute of Toxicology, 30 Baekhak1-Gil, Jeongeup, Jeollabuk-Do, 56212, Republic of Korea
| | - Hyeon Jin Seo
- Jeonbuk Department of Inhalation Research, Inhalation Toxicology Center for Airborne Risk Factor, Korea Institute of Toxicology, 30 Baekhak1-Gil, Jeongeup, Jeollabuk-Do, 56212, Republic of Korea
| | - Kyuhong Lee
- Jeonbuk Department of Inhalation Research, Inhalation Toxicology Center for Airborne Risk Factor, Korea Institute of Toxicology, 30 Baekhak1-Gil, Jeongeup, Jeollabuk-Do, 56212, Republic of Korea.
- Department of Human and Environmental Toxicology, University of Science & Technology, Daejeon, 34113, Republic of Korea.
| |
Collapse
|
2
|
Rahmawati SF, Vos R, Bos IST, Kerstjens HAM, Kistemaker LEM, Gosens R. Function-specific IL-17A and dexamethasone interactions in primary human airway epithelial cells. Sci Rep 2022; 12:11110. [PMID: 35773318 PMCID: PMC9247091 DOI: 10.1038/s41598-022-15393-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Accepted: 06/23/2022] [Indexed: 11/09/2022] Open
Abstract
Asthmatics have elevated levels of IL-17A compared to healthy controls. IL-17A is likely to contribute to reduced corticosteroid sensitivity of human airway epithelium. Here, we aimed to investigate the mechanistic underpinnings of this reduced sensitivity in more detail. Differentiated primary human airway epithelial cells (hAECs) were exposed to IL-17A in the absence or presence of dexamethasone. Cells were then collected for RNA sequencing analysis or used for barrier function experiments. Mucus was collected for volume measurement and basal medium for cytokine analysis. 2861 genes were differentially expressed by IL-17A (Padj < 0.05), of which the majority was not sensitive to dexamethasone (< 50% inhibition). IL-17A did inhibit canonical corticosteroid genes, such as HSD11B2 and FKBP5 (p < 0.05). Inflammatory and goblet cell metaplasia markers, cytokine secretion and mucus production were all induced by IL-17A, and these effects were not prevented by dexamethasone. Dexamethasone did reverse IL-17A-stimulated epithelial barrier disruption, and this was associated with gene expression changes related to cilia function and development. We conclude that IL-17A induces function-specific corticosteroid-insensitivity. Whereas inflammatory response genes and mucus production in primary hAECs in response to IL-17A were corticosteroid-insensitive, corticosteroids were able to reverse IL-17A-induced epithelial barrier disruption.
Collapse
Affiliation(s)
- Siti Farah Rahmawati
- Department of Molecular Pharmacology, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands.,Department of Pharmacology and Clinical Pharmacy, Institut Teknologi Bandung, Bandung, Indonesia.,University of Groningen, University Medical Center Groningen (UMCG), Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands
| | - Rémon Vos
- Department of Molecular Pharmacology, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands.,University of Groningen, University Medical Center Groningen (UMCG), Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands
| | - I Sophie T Bos
- Department of Molecular Pharmacology, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands.,University of Groningen, University Medical Center Groningen (UMCG), Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands
| | - Huib A M Kerstjens
- Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands.,University of Groningen, University Medical Center Groningen (UMCG), Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands
| | - Loes E M Kistemaker
- Department of Molecular Pharmacology, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands.,Aquilo Contract Research, Groningen, The Netherlands.,University of Groningen, University Medical Center Groningen (UMCG), Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands
| | - Reinoud Gosens
- Department of Molecular Pharmacology, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands. .,University of Groningen, University Medical Center Groningen (UMCG), Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands.
| |
Collapse
|